Compare · DSGR vs STE
DSGR vs STE
Side-by-side comparison of Distribution Solutions Group Inc. (DSGR) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- DSGR operates in Consumer Discretionary, while STE operates in Health Care - the two are in different parts of the market.
- STE is the larger of the two at $20.89B, about 13.1x DSGR ($1.59B).
- Over the past year, DSGR is up 15.9% and STE is down 7.2% - DSGR leads by 23.1 points.
- DSGR has been more active in the news (6 items in the past 4 weeks vs 1 for STE).
- STE has more recent analyst coverage (16 ratings vs 1 for DSGR).
- Company
- Distribution Solutions Group Inc.
- STERIS plc (Ireland)
- Price
- $34.50-0.06%
- $214.13+1.63%
- Market cap
- $1.59B
- $20.89B
- 1M return
- +26.19%
- +3.42%
- 1Y return
- +15.89%
- -7.18%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 1
- Recent ratings
- 1
- 16
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest DSGR
- Distribution Solutions Group Announces Timing for Second Quarter Fiscal Year 2026 Results
- Amendment: SEC Form SCHEDULE 13D/A filed by Distribution Solutions Group Inc.
- SEC Form DEFA14A filed by Distribution Solutions Group Inc.
- Distribution Solutions Group Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement, Regulation FD Disclosure
- TestEquity Expands Environmental Chamber Sales Reach with Millennium Alliance Representation Across the Midwest
- Distribution Solutions Group to Be Taken Private by Affiliates of LKCM Headwater Investments for $35.00 Per Common Share in Cash
- President and CEO Lanuza Cesar was granted 20,000 shares, increasing direct ownership by 25% to 100,498 units (SEC Form 4)
- TestEquity Announces New Executive Leadership Team to Drive Growth as the Leading Distribution Platform for Test and Measurement Solutions, Electronics Production Supplies, and Services
- Director Hillman Lee S was granted 4,601 units of Common Stock - Restricted Stock Units, increasing direct ownership by 4% to 111,862 units (SEC Form 4)
- Director Edelson I Steven was granted 4,601 units of Common Stock - Restricted Stock Units, increasing direct ownership by 5% to 103,284 units (SEC Form 4)
Latest STE
- Director Sohi Mohsen exercised 3,781 units of Ordinary Shares at a strike of $71.40 and covered exercise/tax liability with 1,837 units of Ordinary Shares, increasing direct ownership by 9% to 24,305 units (SEC Form 4)
- SEC Form 11-K filed by STERIS plc (Ireland)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam sold $296,968 worth of Ordinary Shares (1,419 units at $209.28), decreasing direct ownership by 4% to 35,259 units (SEC Form 4)
- SEC Form 144 filed by STERIS plc (Ireland)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 401 units of Ordinary Shares, decreasing direct ownership by 1% to 36,678 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 65 units of Ordinary Shares, decreasing direct ownership by 1% to 6,194 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 195 units of Ordinary Shares, decreasing direct ownership by 2% to 12,257 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E covered exercise/tax liability with 150 units of Ordinary Shares, decreasing direct ownership by 1% to 11,332 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare covered exercise/tax liability with 600 units of Ordinary Shares, decreasing direct ownership by 4% to 13,716 units (SEC Form 4)
- President and CEO Carestio Daniel A covered exercise/tax liability with 1,889 units of Ordinary Shares and sold $946,799 worth of Ordinary Shares (4,428 units at $213.82), decreasing direct ownership by 9% to 63,647 units (SEC Form 4)